¼¼°èÀÇ °íÄ®½·Ç÷Áõ Ä¡·á ½ÃÀå : Á¦Ç° À¯Çü, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ªº°(ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«) : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¿¹Ãø(2023-2030³â)
Hypercalcemia Treatment Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2030
»óǰÄÚµå
:
1457348
¸®¼Ä¡»ç
:
Persistence Market Research
¹ßÇàÀÏ
:
2024³â 02¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 223 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
Persistence Market Research´Â ¼¼°è °íÄ®½· Ç÷Áõ Ä¡·á ½ÃÀå¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®À» ¹ßÇ¥ÇÏ°í ¾÷°è ¿ªÇÐ, ¼ºÀå ÃËÁø¿äÀÎ ¹× °úÁ¦ ¹× ½ÅÈï µ¿Çâ¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ °³¿ä¸¦ Á¦°øÇß½À´Ï´Ù. º» º¸°í¼´Â °íÄ®½·Ç÷Áõ Ä¡·á ½ÃÀåÀÇ ±¸Á¶¿¡ ´ëÇÑ ±ÍÁßÇÑ ÅëÂû·ÂÀ» Á¦°øÇϰí 2023³âºÎÅÍ 2030³â±îÁö ½ÃÀåÀÇ ±ËÀûÀ» ¿¹ÃøÇÏ´Â µ¶ÀÚÀûÀÎ µ¥ÀÌÅÍ¿Í Åë°è¸¦ Á¦°øÇÕ´Ï´Ù.
¼¼°èÀÇ °íÄ®½·Ç÷Áõ Ä¡·á ½ÃÀåÀº CAGR 11.8%·Î È®´ëµÇ¾î 2023³â 1,830¸¸ ´Þ·¯¿¡¼ 2030³â ¸»¿¡´Â 4,000¸¸ ´Þ·¯·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ÁÖ¿ä ÀλçÀÌÆ®
°íÄ®½·Ç÷Áõ Ä¡·á ½ÃÀå ±Ô¸ð(2023³â) : 1,830¸¸ ´Þ·¯
¿¹Ãø ½ÃÀå °¡Ä¡(2030³â) : 4,000¸¸ ´Þ·¯
¼¼°è ½ÃÀå ¼ºÀå·ü(CAGR 2023-2030³â) : 11.8%
°ú°Å ½ÃÀå ¼ºÀå·ü(CAGR 2018-2022³â) : 10.8%
°íÄ®½· Ç÷Áõ Ä¡·á ½ÃÀå - º¸°í ¹üÀ§:
°íÄ®½· Ç÷Áõ Ä¡·á ½ÃÀåÀº Ç÷Áß Ä®½· ³óµµÀÇ »ó½ÂÀ» °ü¸®Çϱâ À§ÇÑ ÀǾàǰ, Ä¡·á ¹× °³ÀÔÀ» Æ÷°ýÇÕ´Ï´Ù. ¿ø¹ß¼º ºÎ°©»ó¼± ±â´É Ç×ÁøÁõ, ¾Ç¼º Á¾¾ç °ü·Ã °íÄ®½· Ç÷Áõ ¹× ±âŸ ´ë»ç ÀÌ»ó°ú °°Àº Áúº´Àº °ü·Ã À§Çè°ú ÇÕº´ÁõÀ» ¿ÏÈÇÏ´Â È¿°úÀûÀÎ Ä¡·á Àü·«ÀÌ ÇÊ¿äÇÕ´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿øÀÎÀº ³ôÀº Ä®½· Ç÷ÁõÀÇ À¯º´·ü Áõ°¡, Ä¡·á¹ýÀÇ Áøº¸, °Ç° °ü¸® Àü¹®°¡ ¹× ȯÀÚ ÀÇ½Ä Áõ°¡ÀÔ´Ï´Ù.
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ:
°íÄ®½·Ç÷Áõ Ä¡·á ½ÃÀåÀº ºÎ°©»ó¼± ±â´É Ç×ÁøÁõ, ¾Ï, ½ÅºÎÀü µî Ä®½·Ä¡ÀÇ »ó½ÂÀ¸·Î À̾îÁö´Â ÁúȯÀÇ ÀÌȯÀ²ÀÇ »ó½Â¿¡ ÀÇÇØ Ȱ¼ºÈµË´Ï´Ù. À̹Ì¡ ¹× »ýÈÇÐ °Ë»ç¿Í °°Àº Áø´Ü ±â¼úÀÇ Áøº¸·Î Á¶±â ¹ß°ß°ú ½Å¼ÓÇÑ Ä¡·á °³½Ã°¡ ¿ëÀÌÇØÁö°í ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡, Ä®½Ã¸¶ÀÌ¸ÞÆ½°ú ºñ½ºÆ÷½ºÆ÷³×ÀÌÆ®¸¦ Æ÷ÇÔÇÑ ½Å±Ô ¾àÁ¦ÀÇ µµÀÔÀº º¸´Ù ÀûÀº È¿°úÀûÀÎ Ä¡·á ¿É¼ÇÀ» Á¦°øÇÏ¿© ½ÃÀå ¼ºÀåÀ» ´õ¿í µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ:
Å« ¼ºÀåÀÌ ¿¹»óµÇ´Â °íÄ®½· Ç÷Áõ Ä¡·á ½ÃÀåÀº ³Ä¡¼º °íÄ®½· Ç÷Áõ¿¡ ´ëÇÑ Á¦ÇÑµÈ Ä¡·á ¿É¼Ç°ú ƯÁ¤ ¾à¸®ÇÐ °³ÀÔ°ú °ü·ÃµÈ ºÎÀÛ¿ë°ú °ü·ÃµÈ ¹®Á¦¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½Å±Ô Ä¡·áÁ¦ÀÇ ³ôÀº ºñ¿ë°ú ÀǾàǰ ½ÂÀο¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©ÀÌ ½ÃÀå ħÅõÀÇ À庮ÀÌ µÇ°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡, Áúº´ÀÇ º´Àΰú Ä¡·á¿¡ ´ëÇÑ È¯ÀÚÀÇ ¹ÝÀÀ¿¡´Â °³ÀÎÂ÷°¡ Àֱ⠶§¹®¿¡ °³º°ÈµÈ Á¢±ÙÀÌ ÇÊ¿äÇϸç, Ä¡·áÀÇ ÀÇ»ç°áÁ¤°ú °ü¸® Àü·«¿¡ º¹À⼺À» °¡Á®¿À°í ÀÖ½À´Ï´Ù.
½ÃÀå ±âȸ:
°íÄ®½·Ç÷Áõ Ä¡·á ½ÃÀåÀº ½Å±Ô Ä¡·á Ç¥Àû ¹× Ä¡·á¹ýÀÇ ½Äº°¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸ °³¹ßÀÇ Áö¼ÓÀûÀÎ ³ë·ÂÀ» ÅëÇØ À¯¸ÁÇÑ ±âȸ¸¦ Á¦½ÃÇÕ´Ï´Ù. ºÐÀÚ ÇÁ·ÎÆÄÀϸµ ¹× Ç¥Àû Ä¡·á¸¦ Æ÷ÇÔÇÑ Á¤¹ÐÀÇ·áÀÇ Áøº¸´Â º¸´Ù °³º°ÈµÇ°í È¿°úÀûÀÎ Ä¡·á Á¢±ÙÀÇ ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ´õ¿íÀÌ, ÀÇ·á¿¡¼ÀÇ ÀΰøÁö´É°ú ºòµ¥ÀÌÅÍ ºÐ¼®ÀÇ ÅëÇÕÀº µ¥ÀÌÅÍ Áß½ÉÀÇ ÀÇ»ç°áÁ¤À» ÃËÁøÇϰí, Ä¡·á ¼º°ú¸¦ Çâ»ó½Ã۰í, ½ÃÀå ¼ºÀå°ú Â÷º°È¸¦ ÃËÁøÇÕ´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ ´Ù·ç´Â ÁÖ¿ä Áú¹®
°íÄ®½·Ç÷Áõ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
°íÄ®½·Ç÷Áõ Ä¡·á·Î ä¿ëÀÌ Áõ°¡Çϰí ÀÖ´Â Ä¡·á¹ýÀº ¹«¾ùÀΰ¡?
½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ÁÖ¿ä °úÁ¦¿Í ¾ïÁ¦¿äÀÎÀº ¹«¾ùÀΰ¡?
°íÄ®½· Ç÷Áõ Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº ¾îµò°¡À̸ç Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê´Â ¹«¾ùÀΰ¡?
¼¼°èÀÇ °íÄ®½·Ç÷Áõ Ä¡·á ½ÃÀåÀÇ »õ·Î¿î µ¿Çâ°ú Àå·¡ Àü¸ÁÀº?
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå °³¿ä
½ÃÀåÀÇ ¹üÀ§¿Í Á¤ÀÇ
½ÃÀå ¿ªÇÐ
¼ºÀå ÃËÁø¿äÀÎ
¾ïÁ¦¿äÀÎ
±âȸ
°úÁ¦
ÁÖ¿ä µ¿Çâ
Á¦Ç° ¼ö¸íÁֱ⠺м®
°íÄ®½·Ç÷Áõ Ä¡·á ½ÃÀå : ¹ë·ùüÀÎ
¿øÀç·á °ø±Þ¾÷ü ¸ñ·Ï
Á¦Á¶¾÷ü À϶÷
¸®¼¿·¯ À϶÷
¿ëµµ À϶÷
¼öÀͼº ºÐ¼®
Porter's Five Forces ºÐ¼®
ÁöÁ¤ÇÐÀû ±äÀå: ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâ
°Å½Ã °æÁ¦Àû ¿äÀÎ
¼¼°èÀÇ ¼½Åͺ° Àü¸Á
¼¼°è GDP ¼ºÀå·ü Àü¸Á
¼¼°èÀÇ »óÀ§ ½ÃÀå °³¿ä
¿¹Ãø ¿äÀÎ- °ü·Ã¼º°ú ¿µÇâ
±ÔÁ¦¿Í Á¦Ç°ÀÇ »óȲ
Á¦3Àå ¼¼°èÀÇ °íÄ®½·Ç÷Áõ Ä¡·á ½ÃÀå Àü¸Á: ½ÇÀû(2018-2022³â)°ú ¿¹Ãø(2023-2030³â)
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
½ÃÀå¼ö·®(À¯´Ö) ¿¹Ãø
½ÃÀå ±Ô¸ð¿Í Àü³â´ëºñ ¼ºÀå·ü
Àý´ëÀû ÀÌÀÍÀÇ ±âȸ
½ÃÀå ±Ô¸ð(1¸¸ ´Þ·¯) ºÐ¼®°ú ¿¹Ãø
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®(2013-2016³â)
ÇöÀç ½ÃÀå ±Ô¸ð ¿¹Ãø(2018-2026³â)
¼¼°èÀÇ °íÄ®½·Ç÷Áõ Ä¡·á ½ÃÀå Àü¸Á: Á¦Ç°
¼Ò°³/ ÁÖ¿ä Á¶»ç °á°ú
Á¦Ç°º° °ú°Å ½ÃÀå ±Ô¸ð ¹× ¼ö·®(´ÜÀ§) ºÐ¼®(2018-2022³â)
ÇöÀç ½ÃÀå ±Ô¸ð¿Í Á¦Ç°º° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023-2030³â)
ºñ½ºÆ÷½ºÆ÷³×ÀÌÆ®
Ŭ·Îµå·Î³×ÀÌÆ®
À̹ݵµ·Î³×ÀÌÆ®
ÆÄ¹Ìµå·Î³×ÀÌÆ®
Á¹·¹µå·Ð»ê
Ä®½ÃÅä´Ñ
±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵å
µ¥³ë¼ö¸¿
Ä®½Ã¹Ì¸Þƽ·ù
½ÃÀå ¸Å·Â ºÐ¼® : Á¦Ç°
¼¼°èÀÇ °íÄ®½·Ç÷Áõ Ä¡·á ½ÃÀå Àü¸Á: À¯Åë ä³Î
¼Ò°³/ ÁÖ¿ä Á¶»ç °á°ú
À¯Åëä³Îº° °ú°Å ½ÃÀå ±Ô¸ð¿Í ¼ö·®(´ÜÀ§) ºÐ¼®(2018-2022³â)
ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÆÇ¸Åä³Îº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023-2030³â)
º´¿ø
Ŭ¸®´Ð
µ¶¸³°è ¾à±¹°ú ¾à±¹
½ÃÀå ¸Å·Â ºÐ¼® : À¯Åë ä³Î
Á¦4Àå ¼¼°èÀÇ °íÄ®½·Ç÷Áõ Ä¡·á ½ÃÀå Àü¸Á : Áö¿ª
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
Áö¿ªº° °ú°Å ½ÃÀå ±Ô¸ð ¹× ¼ö·®(´ÜÀ§) ºÐ¼®, 2018³âºÎÅÍ 2022³â
ÇöÀç ½ÃÀå ±Ô¸ð¿Í Áö¿ªº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023-2030³â)
ºÏ¹Ì
À¯·´
µ¿¾Æ½Ã¾Æ
³²¾Æ½Ã¾Æ¿Í ¿À¼¼¾Æ´Ï¾Æ
¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«(MEA)
½ÃÀåÀÇ ¸Å·Â ºÐ¼® :Áö¿ª
Á¦5Àå ºÏ¹ÌÀÇ °íÄ®½·Ç÷Áõ Ä¡·á ½ÃÀå Àü¸Á: ½ÇÀû(2018-2022³â)°ú ¿¹Ãø(2023-2030³â)
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
°¡°Ý ºÐ¼®
°ú°Å ½ÃÀå ±Ô¸ð¿Í ½ÃÀ庰 ¼ö·®(´ÜÀ§) ºÐ¼®(2018-2022³â)
±¹°¡º°
Á¦Ç°º°
À¯Åë ä³Îº°
±¹°¡º° ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¼ö·®(´ÜÀ§) ¿¹Ãø(2023-2030³â)
ÇöÀç ½ÃÀå ±Ô¸ð¿Í Á¦Ç°º° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023-2030³â)
ºñ½ºÆ÷½ºÆ÷³×ÀÌÆ®
Ŭ·Îµå·Î³×ÀÌÆ®
À̹ݵµ·Î³×ÀÌÆ®
ÆÄ¹Ìµå·Î³×ÀÌÆ®
Á¹·¹µå·Ð»ê
Ä®½ÃÅä´Ñ
±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵å
µ¥³ë¼ö¸¿
Ä®½Ã¹Ì¸Þƽ·ù
ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÆÇ¸Åä³Îº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023-2030³â)
º´¿ø
Ŭ¸®´Ð
µ¶¸³°è ¾à±¹°ú ¾à±¹
½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦6Àå À¯·´ÀÇ °íÄ®½·Ç÷Áõ Ä¡·á ½ÃÀå Àü¸Á: ½ÇÀû(2018-2022³â)°ú ¿¹Ãø(2023-2030³â)
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
°¡°Ý ºÐ¼®
°ú°Å ½ÃÀå ±Ô¸ð¿Í ½ÃÀ庰 ¼ö·®(´ÜÀ§) ºÐ¼®(2018-2022³â)
±¹°¡º°
Á¦Ç°º°
À¯Åë ä³Îº°
±¹°¡º° ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¼ö·®(´ÜÀ§) ¿¹Ãø(2023-2030³â)
µ¶ÀÏ
ÇÁ¶û½º
¿µ±¹
ÀÌÅ»¸®¾Æ
½ºÆäÀÎ
·¯½Ã¾Æ
ÅÍŰ
±âŸ À¯·´
ÇöÀç ½ÃÀå ±Ô¸ð¿Í Á¦Ç°º° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023-2030³â)
ºñ½ºÆ÷½ºÆ÷³×ÀÌÆ®
Ŭ·Îµå·Î³×ÀÌÆ®
À̹ݵµ·Î³×ÀÌÆ®
ÆÄ¹Ìµå·Î³×ÀÌÆ®
Á¹·¹µå·Ð»ê
Ä®½ÃÅä´Ñ
±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵å
µ¥³ë¼ö¸¿
Ä®½Ã¹Ì¸Þƽ·ù
ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÆÇ¸Åä³Îº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023-2030³â)
º´¿ø
Ŭ¸®´Ð
µ¶¸³°è ¾à±¹°ú ¾à±¹
½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦7Àå µ¿¾Æ½Ã¾ÆÀÇ °íÄ®½·Ç÷Áõ Ä¡·á ½ÃÀå Àü¸Á: ½ÇÀû(2018-2022³â)°ú ¿¹Ãø(2023-2030³â)
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
°¡°Ý ºÐ¼®
°ú°Å ½ÃÀå ±Ô¸ð¿Í ½ÃÀ庰 ¼ö·®(´ÜÀ§) ºÐ¼®(2018-2022³â)
±¹°¡º°
Á¦Ç°º°
À¯Åë ä³Îº°
±¹°¡º° ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¼ö·®(´ÜÀ§) ¿¹Ãø(2023-2030³â)
ÇöÀç ½ÃÀå ±Ô¸ð¿Í Á¦Ç°º° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023-2030³â)
ºñ½ºÆ÷½ºÆ÷³×ÀÌÆ®
Ŭ·Îµå·Î³×ÀÌÆ®
À̹ݵµ·Î³×ÀÌÆ®
ÆÄ¹Ìµå·Î³×ÀÌÆ®
Á¹·¹µå·Ð»ê
Ä®½ÃÅä´Ñ
±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵å
µ¥³ë¼ö¸¿
Ä®½Ã¹Ì¸Þƽ·ù
ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÆÇ¸Åä³Îº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023-2030³â)
º´¿ø
Ŭ¸®´Ð
µ¶¸³ÀûÀÎ ¾à±¹°ú ¾à±¹
½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦8Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ °íÄ®½·Ç÷Áõ Ä¡·á ½ÃÀå Àü¸Á: ½ÇÀû(2018-2022³â)°ú ¿¹Ãø(2023-2030³â)
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
°¡°Ý ºÐ¼®
°ú°Å ½ÃÀå ±Ô¸ð¿Í ½ÃÀ庰 ¼ö·®(´ÜÀ§) ºÐ¼®(2018-2022³â)
±¹°¡º°
Á¦Ç°º°
À¯Åë ä³Îº°
±¹°¡º° ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¼ö·®(´ÜÀ§) ¿¹Ãø(2023-2030³â)
Àεµ
µ¿³²¾Æ½Ã¾Æ
´ºÁú·£µå
³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ ±âŸ Áö¿ª
ÇöÀç ½ÃÀå ±Ô¸ð¿Í Á¦Ç°º° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023-2030³â)
ºñ½ºÆ÷½ºÆ÷³×ÀÌÆ®
Ŭ·Îµå·Î³×ÀÌÆ®
À̹ݵµ·Î³×ÀÌÆ®
ÆÄ¹Ìµå·Î³×ÀÌÆ®
Á¹·¹µå·Ð»ê
Ä®½ÃÅä´Ñ
±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵å
µ¥³ë¼ö¸¿
Ä®½Ã¹Ì¸Þƽ·ù
ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÆÇ¸Åä³Îº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023-2030³â)
º´¿ø
Ŭ¸®´Ð
µ¶¸³ÀûÀÎ ¾à±¹°ú ¾à±¹
½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦9Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ °íÄ®½·Ç÷Áõ Ä¡·á ½ÃÀå Àü¸Á: ½ÇÀû(2018-2022³â)°ú ¿¹Ãø(2023-2030³â)
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
°¡°Ý ºÐ¼®
°ú°Å ½ÃÀå ±Ô¸ð¿Í ½ÃÀ庰 ¼ö·®(´ÜÀ§) ºÐ¼®(2018-2022³â)
±¹°¡º°
Á¦Ç°º°
À¯Åë ä³Îº°
±¹°¡º° ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¼ö·®(´ÜÀ§) ¿¹Ãø(2023-2030³â)
ºê¶óÁú
¸ß½ÃÄÚ
±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
ÇöÀç ½ÃÀå ±Ô¸ð¿Í Á¦Ç°º° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023-2030³â)
ºñ½ºÆ÷½ºÆ÷³×ÀÌÆ®
Ŭ·Îµå·Î³×ÀÌÆ®
À̹ݵµ·Î³×ÀÌÆ®
ÆÄ¹Ìµå·Î³×ÀÌÆ®
Á¹·¹µå·Ð»ê
Ä®½ÃÅä´Ñ
±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵å
µ¥³ë¼ö¸¿
Ä®½Ã¹Ì¸Þƽ·ù
ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÆÇ¸Åä³Îº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023-2030³â)
º´¿ø
Ŭ¸®´Ð
µ¶¸³ÀûÀÎ ¾à±¹°ú ¾à±¹
½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦10Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ °íÄ®½·Ç÷Áõ Ä¡·á ½ÃÀå Àü¸Á: ½ÇÀû(2018-2022³â)°ú ¿¹Ãø(2023-2030³â)
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
°¡°Ý ºÐ¼®
°ú°Å ½ÃÀå ±Ô¸ð¿Í ½ÃÀ庰 ¼ö·®(´ÜÀ§) ºÐ¼®(2018-2022³â)
±¹°¡º°
Á¦Ç°º°
À¯Åë ä³Îº°
±¹°¡º° ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¼ö·®(´ÜÀ§) ¿¹Ãø(2023-2030³â)
GCC
ÀÌÁýÆ®
³²¾ÆÇÁ¸®Ä«
ºÏ¾ÆÇÁ¸®Ä«
±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
ÇöÀç ½ÃÀå ±Ô¸ð¿Í Á¦Ç°º° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023-2030³â)
ºñ½ºÆ÷½ºÆ÷³×ÀÌÆ®
Ŭ·Îµå·Î³×ÀÌÆ®
À̹ݵµ·Î³×ÀÌÆ®
ÆÄ¹Ìµå·Î³×ÀÌÆ®
Á¹·¹µå·Ð»ê
Ä®½ÃÅä´Ñ
±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵å
µ¥³ë¼ö¸¿
Ä®½Ã¹Ì¸Þƽ·ù
À¯Åëä³Îº° ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¼ö·®(´ÜÀ§) ¿¹Ãø(2023-2030³â)
º´¿ø
Ŭ¸®´Ð
µ¶¸³ÀûÀÎ ¾à±¹°ú ¾à±¹
½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦11Àå °æÀï ±¸µµ
½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â
½ÃÀå ±¸Á¶
½ÃÀ庰 °æÀïµµÀÇ ¸ÅÇÎ
°æÀï ´ë½Ãº¸µå
°Ñº¸±â Á¦Ç° ¿ë·®
±â¾÷ ÇÁ·ÎÆÄÀÏ(»ó¼¼ - °³¿ä, À繫, Àü·«, ÃÖ±Ù µ¿Çâ)
Amgen Inc.
Pfizer Inc.
Mylan NV
Sunovion
Procter And Gamble
Apotex Corporation
Genentech, Inc.
Novartis AG
Bayer AG
Hoffmann La Roche
Atnahs Pharma
Cipla Inc.
Sun Pharmaceuticals Industries Ltd
Dr. Reddy's Laboratories
Aurobindo Pharma Limited
Á¦12Àå ºÎ·Ï
Á¶»ç ¹æ¹ý
Á¶»çÀÇ ÀüÁ¦
µÎÀÚ¾î ¹× ¾à¾î
JHS
¿µ¹® ¸ñÂ÷
Persistence Market Research has recently published an in-depth analysis of the global hypercalcemia treatment market, providing a comprehensive overview of the industry's dynamics, growth drivers, challenges, and emerging trends. This report furnishes valuable insights into the structure of the hypercalcemia treatment market, offering exclusive data and statistics that forecast the market's trajectory from 2023 to 2030.
The global hypercalcemia treatment market is forecast to expand at a CAGR of 11.8% and thereby increase from a value of US$18.3 Mn in 2023, to US$40 Mn by the end of 2030.
Key Insights:
Hypercalcemia Treatment Market Size (2023E): US$18.3 Mn
Projected Market Value (2030F): US$40.0 Mn
Global Market Growth Rate (CAGR 2023 to 2030): 11.8%
Historical Market Growth Rate (CAGR 2018 to 2022): 10.8%
Hypercalcemia Treatment Market - Report Scope:
The hypercalcemia treatment market encompasses a range of pharmaceuticals, therapies, and interventions aimed at managing elevated levels of calcium in the blood. Conditions such as primary hyperparathyroidism, malignancy-related hypercalcemia, and other metabolic disorders necessitate effective treatment strategies to mitigate associated risks and complications. Market growth is primarily driven by the increasing prevalence of hypercalcemia, advancements in treatment modalities, and growing awareness among healthcare professionals and patients.
Market Growth Drivers:
The hypercalcemia treatment market is fueled by the rising incidence of conditions leading to elevated calcium levels, such as hyperparathyroidism, cancer, and renal failure. Technological advancements in diagnostic techniques, including imaging modalities and biochemical assays, facilitate early detection and prompt initiation of treatment, driving market expansion. Additionally, the introduction of novel pharmaceutical agents, including calcimimetics and bisphosphonates, offers more targeted and efficacious treatment options, further augmenting market growth.
Market Restraints:
Despite significant growth prospects, the hypercalcemia treatment market faces challenges associated with limited treatment options for refractory hypercalcemia and adverse effects associated with certain pharmacological interventions. Furthermore, the high cost of novel therapeutics and the stringent regulatory framework governing drug approval pose barriers to market penetration. Additionally, variations in disease etiology and patient response to treatment necessitate personalized approaches, adding complexity to therapeutic decision-making and management strategies.
Market Opportunities:
The hypercalcemia treatment market presents promising opportunities driven by ongoing research and development initiatives focused on identifying novel therapeutic targets and treatment modalities. Advancements in precision medicine, including molecular profiling and targeted therapy, hold potential for more personalized and effective treatment approaches. Moreover, the integration of artificial intelligence and big data analytics in healthcare facilitates data-driven decision-making and enhances treatment outcomes, fostering market growth and differentiation.
Key Questions Answered in the Report:
What are the primary factors driving the growth of the hypercalcemia treatment market?
Which therapeutic modalities are witnessing increased adoption in the management of hypercalcemia?
What are the key challenges and restraints hindering market growth?
Who are the leading players in the hypercalcemia treatment market, and what are their strategic initiatives?
What are the emerging trends and future prospects in the global hypercalcemia treatment market?
Competitive Intelligence and Business Strategy:
Leading pharmaceutical companies, including., dominate the hypercalcemia treatment market through a combination of product innovation, strategic partnerships, and acquisitions. These companies invest significantly in research and development to expand their product portfolios and address unmet medical needs in hypercalcemia management. Collaboration with academic institutions and research organizations facilitates the development of novel therapeutics and treatment algorithms, enhancing market competitiveness and driving long-term growth.
Key Companies Profiled:
Amgen Inc.
Pfizer Inc.
Mylan N. V.
Sunovion
Procter And Gamble
Apotex Corporation
Genentech, Inc.
Novartis AG
Bayer AG
Hoffmann La Roche
Hypercalcemia Treatment Market Research Segmentation:
By Product:
Clodronate
Ibandronate
Pamidronate
Zoledronic Acid
Calcitonin
Glucocorticoids
Denosumab
Calcimimetics
By Distribution Channel:
Hospitals
Clinics
Independent Pharmacy & Drug Stores
By Region:
North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East & Africa
Table of Contents
1. Executive Summary
1.1. Global Hypercalcemia Treatment Market Snapshot, 2023 and 2030
1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Product Lifecycle Analysis
2.4. Hypercalcemia Treatment Market: Value Chain
2.4.1. List of Raw Material Supplier
2.4.2. List of Manufacturers
2.4.3. List of Distributors
2.4.4. List of Applications
2.4.5. Profitability Analysis
2.5. Porter Five Force's Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
2.7.1. Global Sectorial Outlook
2.7.2. Global GDP Growth Outlook
2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Product Landscape
3. Global Hypercalcemia Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
3.1. Key Highlights
3.1.1. Market Volume (Units) Projections
3.1.2. Market Size and Y-o-Y Growth
3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Mn) Analysis and Forecast
3.2.1. Historical Market Size Analysis, 2013-2016
3.2.2. Current Market Size Forecast, 2018-2026
3.3. Global Hypercalcemia Treatment Market Outlook: Product
3.3.1. Introduction / Key Findings
3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Product, 2018 - 2022
3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
3.3.3.1. Bisphosphonates
3.3.3.1.1. Clodronate
3.3.3.1.2. Ibandronate
3.3.3.1.3. Pamidronate
3.3.3.1.4. Zoledronic Acid
3.3.3.2. Calcitonin
3.3.3.3. Glucocorticoids
3.3.3.4. Denosumab
3.3.3.5. Calcimimetics
3.4. Market Attractiveness Analysis: Product
3.5. Global Hypercalcemia Treatment Market Outlook: Distribution Channel
3.5.1. Introduction / Key Findings
3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Distribution Channel, 2018 - 2022
3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
3.5.3.1. Hospitals
3.5.3.2. Clinics
3.5.3.3. Independent Pharmacy & Drug Stores
3.6. Market Attractiveness Analysis: Distribution Channel
4. Global Hypercalcemia Treatment Market Outlook: Region
4.1. Key Highlights
4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
4.3.1. North America
4.3.2. Europe
4.3.3. East Asia
4.3.4. South Asia and Oceania
4.3.5. Latin America
4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region
5. North America Hypercalcemia Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
5.3.1. By Country
5.3.2. By Product
5.3.3. By Distribution Channel
5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
5.4.1. U.S.
5.4.2. Canada
5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
5.5.1. Bisphosphonates
5.5.1.1. Clodronate
5.5.1.2. Ibandronate
5.5.1.3. Pamidronate
5.5.1.4. Zoledronic Acid
5.5.2. Calcitonin
5.5.3. Glucocorticoids
5.5.4. Denosumab
5.5.5. Calcimimetics
5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
5.6.1. Hospitals
5.6.2. Clinics
5.6.3. Independent Pharmacy & Drug Stores
5.7. Market Attractiveness Analysis
6. Europe Hypercalcemia Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
6.3.1. By Country
6.3.2. By Product
6.3.3. By Distribution Channel
6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
6.4.1. Germany
6.4.2. France
6.4.3. U.K.
6.4.4. Italy
6.4.5. Spain
6.4.6. Russia
6.4.7. Turkiye
6.4.8. Rest of Europe
6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
6.5.1. Bisphosphonates
6.5.1.1. Clodronate
6.5.1.2. Ibandronate
6.5.1.3. Pamidronate
6.5.1.4. Zoledronic Acid
6.5.2. Calcitonin
6.5.3. Glucocorticoids
6.5.4. Denosumab
6.5.5. Calcimimetics
6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
6.6.1. Hospitals
6.6.2. Clinics
6.6.3. Independent Pharmacy & Drug Stores
6.7. Market Attractiveness Analysis
7. East Asia Hypercalcemia Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
7.3.1. By Country
7.3.2. By Product
7.3.3. By Distribution Channel
7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
7.4.1. China
7.4.2. Japan
7.4.3. South Korea
7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
7.5.1. Bisphosphonates
7.5.1.1. Clodronate
7.5.1.2. Ibandronate
7.5.1.3. Pamidronate
7.5.1.4. Zoledronic Acid
7.5.2. Calcitonin
7.5.3. Glucocorticoids
7.5.4. Denosumab
7.5.5. Calcimimetics
7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
7.6.1. Hospitals
7.6.2. CLINICS
7.6.3. INDEPENDENT PHARMACY & DRUG STORES
7.7. Market Attractiveness Analysis
8. South Asia & Oceania Hypercalcemia Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
8.3.1. By Country
8.3.2. By Product
8.3.3. By Distribution Channel
8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
8.4.1. India
8.4.2. Southeast Asia
8.4.3. ANZ
8.4.4. Rest of South Asia & Oceania
8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
8.5.1. Bisphosphonates
8.5.1.1. Clodronate
8.5.1.2. Ibandronate
8.5.1.3. Pamidronate
8.5.1.4. Zoledronic Acid
8.5.2. Calcitonin
8.5.3. Glucocorticoids
8.5.4. Denosumab
8.5.5. Calcimimetics
8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
8.6.1. Hospitals
8.6.2. CLINICS
8.6.3. INDEPENDENT PHARMACY & DRUG STORES
8.7. Market Attractiveness Analysis
9. Latin America Hypercalcemia Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
9.3.1. By Country
9.3.2. By Product
9.3.3. By Distribution Channel
9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
9.5.1. Bisphosphonates
9.5.1.1. Clodronate
9.5.1.2. Ibandronate
9.5.1.3. Pamidronate
9.5.1.4. Zoledronic Acid
9.5.2. Calcitonin
9.5.3. Glucocorticoids
9.5.4. Denosumab
9.5.5. Calcimimetics
9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
9.6.1. Hospitals
9.6.2. CLINICS
9.6.3. INDEPENDENT PHARMACY & DRUG STORES
9.7. Market Attractiveness Analysis
10. Middle East & Africa Hypercalcemia Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
10.3.1. By Country
10.3.2. By Product
10.3.3. By Distribution Channel
10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
10.4.1. GCC
10.4.2. Egypt
10.4.3. South Africa
10.4.4. Northern Africa
10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
10.5.1. Bisphosphonates
10.5.1.1. Clodronate
10.5.1.2. Ibandronate
10.5.1.3. Pamidronate
10.5.1.4. Zoledronic Acid
10.5.2. Calcitonin
10.5.3. Glucocorticoids
10.5.4. Denosumab
10.5.5. Calcimimetics
10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
10.6.1. Hospitals
10.6.2. CLINICS
10.6.3. INDEPENDENT PHARMACY & DRUG STORES
10.7. Market Attractiveness Analysis
11. Competition Landscape
11.1. Market Share Analysis, 2022
11.2. Market Structure
11.2.1. Competition Intensity Mapping By Market
11.2.2. Competition Dashboard
11.2.3. Apparent Product Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
11.3.1. Amgen Inc.
11.3.1.1. Overview
11.3.1.2. Segments and Product
11.3.1.3. Key Financials
11.3.1.4. Market Developments
11.3.1.5. Market Strategy
11.3.2. Pfizer Inc.
11.3.2.1. Overview
11.3.2.2. Segments and Product
11.3.2.3. Key Financials
11.3.2.4. Market Developments
11.3.2.5. Market Strategy
11.3.3. Mylan N. V.
11.3.3.1. Overview
11.3.3.2. Segments and Product
11.3.3.3. Key Financials
11.3.3.4. Market Developments
11.3.3.5. Market Strategy
11.3.4. Sunovion
11.3.4.1. Overview
11.3.4.2. Segments and Product
11.3.4.3. Key Financials
11.3.4.4. Market Developments
11.3.4.5. Market Strategy
11.3.5. Procter And Gamble
11.3.5.1. Overview
11.3.5.2. Segments and Product
11.3.5.3. Key Financials
11.3.5.4. Market Developments
11.3.5.5. Market Strategy
11.3.6. Apotex Corporation
11.3.6.1. Overview
11.3.6.2. Segments and Product
11.3.6.3. Key Financials
11.3.6.4. Market Developments
11.3.6.5. Market Strategy
11.3.7. Genentech, Inc.
11.3.7.1. Overview
11.3.7.2. Segments and Product
11.3.7.3. Key Financials
11.3.7.4. Market Developments
11.3.7.5. Market Strategy
11.3.8. Novartis AG
11.3.8.1. Overview
11.3.8.2. Segments and Product
11.3.8.3. Key Financials
11.3.8.4. Market Developments
11.3.8.5. Market Strategy
11.3.9. Bayer AG
11.3.9.1. Overview
11.3.9.2. Segments and Product
11.3.9.3. Key Financials
11.3.9.4. Market Developments
11.3.9.5. Market Strategy
11.3.10. Hoffmann La Roche
11.3.10.1. Overview
11.3.10.2. Segments and Product
11.3.10.3. Key Financials
11.3.10.4. Market Developments
11.3.10.5. Market Strategy
11.3.11. Atnahs Pharma
11.3.11.1. Overview
11.3.11.2. Segments and Product
11.3.11.3. Key Financials
11.3.11.4. Market Developments
11.3.11.5. Market Strategy
11.3.12. Cipla Inc.
11.3.12.1. Overview
11.3.12.2. Segments and Product
11.3.12.3. Key Financials
11.3.12.4. Market Developments
11.3.12.5. Market Strategy
11.3.13. Sun Pharmaceuticals Industries Ltd
11.3.13.1. Overview
11.3.13.2. Segments and Product
11.3.13.3. Key Financials
11.3.13.4. Market Developments
11.3.13.5. Market Strategy
11.3.14. Dr. Reddy's Laboratories
11.3.14.1. Overview
11.3.14.2. Segments and Product
11.3.14.3. Key Financials
11.3.14.4. Market Developments
11.3.14.5. Market Strategy
11.3.15. Aurobindo Pharma Limited
11.3.15.1. Overview
11.3.15.2. Segments and Product
11.3.15.3. Key Financials
11.3.15.4. Market Developments
11.3.15.5. Market Strategy
12. Appendix
12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations
°ü·ÃÀÚ·á